ArticleFrontiers in immunology2025
Epithelial extracellular vesicles induce inflammation and neutrophil activation in the
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Introduction: Cystic fibrosis (CF) is an autosomal recessive disorder, which manifests in many organ systems including the lungs. Chronic inflammation is a hallmark of CF lung disease leading to bronchiectasis and lung function decline. This is worsened by airway colonization and recurrent infections due to opportunistic pathogens such as Methods: CF bronchial epithelial cells (CFBEs) and control bronchial epithelial cells (16HBEs) were infected with PA for 24 hours followed by EV isolation, which were used to treat uninfected CFBE and 16HBEs to assess expression and secretion of pro-inflammatory markers. In addition, the effects of EVs on neutrophil migration and activation were determined as well as the role of CFTR deficiency by using CFTR modulator therapy (Elexacaftor/Tezacaftor/Ivacaftor). Results: EVs derived from PA infected CFBEs (EVpPAs) increased IL-6, IL-8, and TNFα expression and neutrophil activation in CFBEs but not in 16HBEs. Interestingly, the effect of EVpPAs on inflammation was not attenuated by pre-treatment with ETI. Discussion: EVs from the PA-infected CF bronchial epithelium seem to facilitate an autocrine and paracrine pro-inflammatory response that is not attenuated by ETI treatment, suggesting a novel contribution of EVs to the chronic inflammatory phenotype observed in the PA-infected CF lung.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.